Heath Lukatch Vaxcyte, Inc. (PCVX) insider trading activity

PCVX Quotes by TradingView

Heath Lukatch is Director of Vaxcyte, Inc.. Currently has a direct ownership of 7,175 shares of PCVX, which is worth approximately $580,959. The most recent transaction as insider was on Jun 06, 2024, when has been sold 1,550 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 7.18K
0% 3M change
27.56% 12M change
Total Value Held $580,959

Heath Lukatch Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 06 2024
BUY
Grant, award, or other acquisition
-
1,550 Added 17.77%
7,175 Common Stock
Jan 31 2024
SELL
Open market or private sale
$357,500 $71.5 p/Share
5,000 Reduced 47.06%
5,625 Common Stock
Jan 31 2024
BUY
Exercise of conversion of derivative security
$80,000 $16.0 p/Share
5,000 Added 32.0%
10,625 Common Stock
Jan 29 2024
SELL
Open market or private sale
$270,000 $67.5 p/Share
4,000 Reduced 41.56%
5,625 Common Stock
Jan 29 2024
BUY
Exercise of conversion of derivative security
$64,000 $16.0 p/Share
4,000 Added 29.36%
9,625 Common Stock
Jan 02 2024
SELL
Open market or private sale
$831,610 $63.97 p/Share
13,000 Reduced 69.8%
5,625 Common Stock
Jan 02 2024
BUY
Exercise of conversion of derivative security
$208,000 $16.0 p/Share
13,000 Added 41.11%
18,625 Common Stock
Jun 13 2023
BUY
Grant, award, or other acquisition
-
2,500 Added 30.77%
5,625 Common Stock
Jan 10 2023
SELL
Open market or private sale
$14,549 $46.19 p/Share
315 Reduced 9.16%
3,125 Common Stock
Jan 10 2023
BUY
Exercise of conversion of derivative security
$5,040 $16.0 p/Share
315 Added 8.39%
3,440 Common Stock
Dec 12 2022
SELL
Open market or private sale
$14,468 $43.19 p/Share
335 Reduced 9.68%
3,125 Common Stock
Dec 12 2022
BUY
Exercise of conversion of derivative security
$5,360 $16.0 p/Share
335 Added 8.83%
3,460 Common Stock
Nov 10 2022
SELL
Open market or private sale
$197,242 $45.5 p/Share
4,335 Reduced 58.11%
3,125 Common Stock
Nov 10 2022
BUY
Exercise of conversion of derivative security
$69,360 $16.0 p/Share
4,335 Added 36.75%
7,460 Common Stock
Oct 26 2022
SELL
Open market or private sale
$153,000 $38.25 p/Share
4,000 Reduced 56.14%
3,125 Common Stock
Oct 26 2022
BUY
Exercise of conversion of derivative security
$64,000 $16.0 p/Share
4,000 Added 35.96%
7,125 Common Stock
Oct 24 2022
SELL
Open market or private sale
$105,857 $35.11 p/Share
3,015 Reduced 49.1%
3,125 Common Stock
Oct 24 2022
BUY
Exercise of conversion of derivative security
$48,240 $16.0 p/Share
3,015 Added 32.93%
6,140 Common Stock
Jun 01 2022
BUY
Grant, award, or other acquisition
-
3,125 Added 50.0%
3,125 Common Stock

Also insider at

STSA
Satsuma Pharmaceuticals, Inc. Healthcare
Director
INGN
Inogen Inc Healthcare
Director
FLXN
Flexion Therapeutics Inc
Director
HL

Heath Lukatch

Director
San Carlos, CA

Track Institutional and Insider Activities on PCVX

Follow Vaxcyte, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PCVX shares.

Notify only if

Insider Trading

Get notified when an Vaxcyte, Inc. insider buys or sells PCVX shares.

Notify only if

News

Receive news related to Vaxcyte, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on PCVX